Lilly and Boehringer’s insulin glargine product gets European marketing approval
The insulin glargine product is the first insulin treatment approved through the European Medicines Agency’s (EMA’s) biosimilar pathway and the fourth diabetes product approved in the European Union
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.